Versigent Has Already Run, But I Still See More Upside
Versigent reported a strong first full quarter as an independent company, with sales up 10.8 percent and adjusted EBITDA up 24.8 percent. The article notes the stock is less cheap than shortly after the Aptiv separation, with valuation near 5.1 times expected 2026 adjusted EBITDA, while flagging debt and weak first-half cash conversion as watch points.
Why it matters — The article assesses Versigent's post-separation financial performance and valuation, giving VGNT watchers a view of near-term earnings strength alongside risks around debt and cash conversion.